The stock's rise snapped a four-day losing streak.

Johnson & Johnson (J&J) has agreed to pay $132 per share to acquire Intra-Cellular Therapies Inc. in a deal valued at about $14.6 billion, taking ownership of Caplyta (lumateperone), a once-daily oral ...

AbbVie (ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd, have entered into an option-to-license agreement ...

ConcertAI, a leader in oncology predictive, generative, and agentic AI SaaS and Real-World Data (RWD) solutions for healthcare and life sciences, today outlined its FY2024 business results, key ...

AbbVie and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd., entered an option to license agreement to ...

In its latest attempt to bulk up its cancer drug portfolio, AbbVie has signed a new licensing agreement with China-based Simcere Zaiming to develop a treatment for myeloma, a type of blood cancer, in ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $175.17 which represents a decrease of $-3.33 or -1.87% from the prior close of $178.5. The stock opened at $176.86 and touched a low of ...

Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated th ...

AbbVie (NYSE:ABBV) and AbCellera (NASDAQ:ABCL) have expanded their collaboration to include the discovery of T-cell engagers for the treatment of cancer. Under the deal, AbCellera (NASDAQ:ABCL) will ...

Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer ...